Galmed Pharmaceuticals Business Summary

Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company that operates primarily through the development of its lead investigational compound, Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate. The company currently generates no commercial revenue, relying on equity financing, at-the-market (ATM) facilities, and potential future licensing or milestone payments from strategic partnerships. Its business segments are bifurcated into liver disease therapeutics—specifically targeting Non-Alcoholic Steatohepatitis (NASH) and fibrosis—and an expanding oncology pipeline focused on gastrointestinal and cardiometabolic indications. Galmed competes directly with clinical-stage peers such as 60 Degrees Pharmaceuticals, Entero Therapeutics, Portage Biotech, and KALA BIO. Within this landscape, Galmed distinguishes itself by pivoting its core SCD1-inhibitor technology toward oncological applications to mitigate the high-risk profile of the NASH market while maintaining a lean, micro-cap operational structure. The company was co-founded by Allen Baharaff, who has served as President and CEO since 2012, bringing a background in finance and law from the London School of Economics and Cambridge University. The leadership team includes Chief Financial Officer Doron Cohen, formerly of Tangram Strategic, Chief Operating Officer Guy Nehemya, and Chief Scientific Officer Dr. Liat Hayardeny, a veteran of Teva Pharmaceutical Industries. The board is led by Lead Independent Director Dr. David Sidransky, a renowned oncologist from Johns Hopkins University. Notable institutional backing includes positions from Heights Capital Management, Two Sigma Investments, and Citadel Advisors, reflecting a shareholder base focused on high-volatility clinical catalysts. As of February 2026, the management is focused on a strategic capital restructuring, including a proposed reverse stock split to maintain its Nasdaq listing and support the advancement of Phase 1/2 trials in gastrointestinal oncology.